Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21444608 | 0.71 | ALDH1A1 (0.32) | ALDH1A1TSHRFGFR4 | |
| SCHEMBL5181997 | 0.71 | LMNA (0.53) | ALDH1A1TSHRFGFR4LMNAALOX15 | |
| SCHEMBL9499003 | 0.71 | LMNA (0.53) | ALDH1A1TSHRFGFR4LMNAALOX15 | |
| SCHEMBL9498997 | 0.71 | LMNA (0.53) | ALDH1A1TSHRFGFR4LMNAALOX15 | |
| Acrylamide SCHEMBL27788827 | 0.70 | ALDH1A1 (0.61) | ALDH1A1TSHRFGFR4LMNAALOX15 | |
| SCHEMBL20861922 | 0.70 | ALDH1A1 (0.45) | ALDH1A1TSHRFGFR4LMNAALOX15 | |
| SCHEMBL19140922 | 0.70 | — | — | |
| SCHEMBL5327633 | 0.69 | — | — | |
| Carbamic Acid SCHEMBL27788828 | 0.69 | ALDH1A1 (0.43) | ALDH1A1TSHRFGFR4LMNAALOX15 | |
| Ethylene SCHEMBL27692988 | 0.68 | LMNA (0.50) | ALDH1A1TSHRFGFR4LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885FGFR4 1772/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TSHR 3319/4885FGFR4 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.